Table 2.
Results of the pairwise comparisons in the network meta-analysis between antiviral agents for COVID-19.
| Antiviral Agents * | Nirmatrelvir Plus Ritonavir | Remdesivir | Molnupiravir | Placebo |
|---|---|---|---|---|
| Nirmatrelvir plus ritonavir | 0.89 (0.17–4.69) | 0.17 (0.07–0.39) | 0.12 (0.06–0.24) | |
| Remdesivir | 1.12 (0.21–5.88) | 0.19 (0.04–0.89) | 0.13 (0.03–0.57)) | |
| Molnupiravir | 5.85 (2.54–13.46) | 5.22 (1.13–24.22) | 0.67 (0.46–0.99) | |
| Placebo | 8.68 (4.15–18.17) | 7.75 (1.76–34.22) | 1.48 (1.01–2.18) |
* Odds ratio and 95% confidence interval were presented with drugs on the column as the reference.